Parkinson's disease crisis — also termed akinetic crisis (AC), parkinsonism-hyperpyrexia syndrome (PHS), or neuroleptic malignant-like syndrome — is a life-threatening, acute exacerbation characterized by severe akinesia, rigidity, hyperthermia, altered consciousness, dysphagia, and autonomic instability, most commonly triggered by abrupt withdrawal or reduction of dopaminergic medications or intercurrent infection. [1-3] It occurs in approximately 0.3% of PD patients per year and carries significant mortality if not recognized early. [4]
1. History
- Medication changes: Any recent discontinuation, dose reduction, or missed doses of levodopa or other dopaminergic agents — the single most common precipitant [1][5]
- Timing: Onset typically over hours to days; ask about compliance, pharmacy issues, NPO status, recent surgery, or hospitalization where meds were held [2][6]
- Intercurrent illness: Fever, URI, UTI, pneumonia — infections are the second most common trigger [3][5]
- DBS patients: Ask about battery failure, device malfunction, or recent programming changes [2][6]
- Symptom progression: Worsening rigidity → immobility → inability to swallow medications → fever → confusion (a vicious cycle)
- Associated symptoms: Dysphagia, diaphoresis, urinary incontinence, chest wall rigidity, dyspnea
- Important negatives: Exposure to dopamine-blocking agents (antipsychotics, metoclopramide), recent anesthesia, serotonergic drug use
2. Alarm Features
- Temperature >38°C without an apparent infectious source — should be considered akinetic crisis until proven otherwise [5]
- Severe "lead-pipe" rigidity unresponsive to usual rescue doses of levodopa [3]
- Altered consciousness (stupor, delirium, coma) [7]
- Autonomic instability: labile BP, tachycardia, profuse diaphoresis [1][8]
- Dysphagia with inability to take oral medications (escalation trigger)
- Signs of rhabdomyolysis: dark urine, oliguria, markedly elevated CK [1][9]
- Respiratory compromise from chest wall/diaphragmatic rigidity [8]
3. Medications
Precipitating medications
- Abrupt withdrawal of levodopa/carbidopa, dopamine agonists, amantadine, COMT inhibitors, or MAO-B inhibitors [1][5]
- Addition of dopamine receptor blockers: haloperidol, droperidol, metoclopramide, prochlorperazine, promethazine [2]
- Serotonergic agents (risk of overlapping serotonin syndrome) [8][10]
Treatment medications
- Reinstate dopaminergic therapy immediately — levodopa/carbidopa via NG tube if unable to swallow [1][7]
- IV amantadine (200 mg BID–TID) — one of the few parenteral dopaminergic options [11]
- Subcutaneous apomorphine — rapid-acting dopamine agonist; useful when oral route unavailable [11-12]
- Subcutaneous foslevodopa — emerging parenteral option (off-label for crisis) [11]
- Bromocriptine 2.5 mg PO/NG q8h — adjunctive dopaminergic therapy [7-8]
- Dantrolene 1–2.5 mg/kg IV — for severe rigidity and hyperthermia [1][8]
- Lorazepam — for mild rigidity and agitation [8]
- High-dose IV methylprednisolone — proposed adjunctive therapy based on limited trial data [2]
Contraindicated medications
- All dopamine receptor blockers (typical and atypical antipsychotics, antiemetics like metoclopramide) [2]
- Anticholinergics in elderly (cognitive worsening) [13]
4. Diet
- NPO in acute crisis due to dysphagia and aspiration risk
- Aggressive IV fluid resuscitation — target urine output ~200–300 mL/hr if rhabdomyolysis present [8]
- Once stabilized: protein intake should be separated from levodopa doses by ≥1 hour (protein competes with levodopa absorption) [14]
- Treat constipation aggressively — impaired GI motility reduces levodopa absorption
5. Review of Systems
- Neuro: Level of consciousness, rigidity severity, tremor, ability to speak/swallow
- Respiratory: Dyspnea, chest wall rigidity, aspiration symptoms
- CV: Palpitations, orthostatic symptoms, chest pain
- GI: Dysphagia, constipation, nausea, last oral intake
- GU: Urine output, color (dark = rhabdomyolysis), incontinence
- Psych: Hallucinations, paranoia, agitation, panic (PD psychosis may coexist) [2]
- MSK: Muscle pain, cramps
6. Collateral History and Family History
- Exact medication list and timing — obtain from caregiver, pharmacy, or medication bottles; confirm last dose taken [15]
- Baseline functional status and Hoehn & Yahr stage
- DBS parameters if applicable — last programming visit, battery check
- Recent hospitalizations or procedures where medications may have been held
- Caregiver reliability — medication compliance, ability to administer meds
- Family history is less relevant in the acute crisis but may inform underlying PD diagnosis
7. Risk Factors
- Advanced PD (higher Hoehn & Yahr stage) [5]
- Older age [5]
- Polypharmacy with dopaminergic agents (more drugs to disrupt)
- History of prior akinetic crisis (recurrence rate documented) [5]
- Severe wearing-off phenomenon [5]
- Dehydration, hot weather [1]
- Recent surgery or hospitalization (medications held perioperatively)
- DBS patients undergoing medication adjustments [2][6]
- Cognitive impairment (poor self-management)
- Less than one-third of PD patients in the ED receive their home carbidopa-levodopa, and fewer than 10% receive it on time [15]
8. Differential Diagnosis
- Neuroleptic malignant syndrome (NMS): Clinically indistinguishable from PHS; differentiated by exposure to dopamine-blocking agent rather than withdrawal of dopaminergic therapy [2][8]
- Serotonin syndrome: Hyperreflexia, clonus, myoclonus, and shivering distinguish it from the lead-pipe rigidity and diminished reflexes of PHS/NMS [8]
- Sepsis: Fever + altered mental status; may coexist as a trigger — always evaluate for infection [5]
- Malignant hyperthermia: Anesthetic exposure context [8]
- Lethal catatonia: Stereotypy, cataplexy, mannerisms help differentiate [8]
- Severe "off" episode: Lacks hyperthermia, CK elevation, and consciousness disturbance [2]
- Subdural hematoma: Consider in PD patients with falls and acute worsening [2]
- Heat stroke, drug intoxication (amphetamines, cocaine, MDMA) [8]
- NMDA-receptor encephalitis: Can mimic NMS [6]
9. Past Medical History
- Duration and stage of PD (Hoehn & Yahr)
- Prior episodes of akinetic crisis or NMS-like events [5]
- DBS implantation — device type, settings, battery status
- History of psychosis, dementia, impulse control disorders
- Renal function (impacts rhabdomyolysis management)
- Cardiac history (autonomic instability → demand ischemia risk) [8]
- Swallowing difficulties at baseline
10. Physical Exam
Vital signs
- Hyperthermia (>38°C, may exceed 40°C) [1][8]
- Tachycardia, labile blood pressure (hypertensive or hypotensive swings) [8]
- Tachypnea, hypoxia (respiratory muscle rigidity)
Focused exam
- Severe "lead-pipe" rigidity — uniform resistance through full passive ROM, often unresponsive to levodopa [3][8]
- Altered consciousness: stupor, mutism, catatonic-like state [7]
- Profuse diaphoresis, pallor [16]
- Sialorrhea [16]
- Dysphagia assessment (can patient swallow medications?)
- Skin: check for pressure injuries (immobility), compartment syndrome signs (rare, from rhabdomyolysis) [8]
- Reflexes: typically diminished or normal (vs. hyperreflexia in serotonin syndrome) [8]
11. Lab Studies
- CK (creatine kinase): Markedly elevated, often >10,000 U/L; may be normal early and rise over days [5][8]
- BMP: Hyperkalemia, hypocalcemia, metabolic acidosis, AKI (creatinine) [8]
- CBC: Leukocytosis is common [8]
- LFTs: Transient elevations of LDH, alkaline phosphatase, aminotransferases [8]
- Urinalysis: Myoglobinuria
- Lactate: Elevated in severe cases
- Troponin: May be elevated from demand ischemia [8]
- Coagulation studies: DIC screen (fibrinogen, D-dimer, PT/INR) — DIC is a life-threatening complication [1][9]
- Blood cultures, UA, CXR: Rule out infectious trigger [5]
- Serum magnesium, phosphorus, calcium: Electrolyte derangements common [8]
12. Imaging
- Chest X-ray: Aspiration pneumonia, pneumonia as trigger
- CT head without contrast: If altered mental status — rule out subdural hematoma (especially with fall history), stroke [2]
- CT abdomen/pelvis: If concern for bowel obstruction or ileus (severe constipation in PD)
- DAT-SPECT: Not emergent, but can confirm akinetic crisis by showing near-complete loss of striatal dopamine transporter binding ("burst striatum" pattern) during crisis, with recovery afterward [17]
13. Special Tests
- Point-of-care ultrasound: Assess volume status, cardiac function, IVC collapsibility
- Bedside swallow evaluation: Determines if oral medications can be given safely
- Continuous telemetry: Autonomic instability with arrhythmia risk
- Urine myoglobin: Confirms rhabdomyolysis
- No validated scoring system exists specifically for akinetic crisis severity, though the Woodbury three-stage system for NMS severity (focused on catatonia) has been described [8]
14. ECG
- Indications: All patients — autonomic instability, electrolyte derangements, and cardiac risk
- Findings to watch for:
- Sinus tachycardia (most common)
- QTc prolongation (baseline from dopaminergic agents; worsened by electrolyte abnormalities)
- Peaked T waves (hyperkalemia from rhabdomyolysis)
- ST changes (demand ischemia / type 2 MI) [8]
- Arrhythmias (cardiac complication of crisis) [9]
15. Assessment
Akinetic crisis represents the most severe end of a continuous spectrum of acute akinetic states in PD. [3] The hallmark is transient levodopa-resistance distinguishing it from routine "off" episodes. [4] The classic tetrad is:
- Severe akinesia/rigidity
- Hyperthermia
- Altered consciousness
- Autonomic dysfunction
Complications include rhabdomyolysis, DIC, acute renal failure, aspiration pneumonia, pulmonary embolism, cardiac arrhythmias, and critical illness neuromyopathy. [1][9] Mortality is significant — in one large series, 31.3% of patients failed to recover to their pre-crisis baseline. [5] Forme fruste presentations (incomplete features) also occur and should not be dismissed. [4]
16. Treatment Plan
Initial stabilization (ICU-level care)
- ABCs: Intubation if respiratory compromise from rigidity or aspiration [8]
- Aggressive IV fluids: Target UOP 200–300 mL/hr for rhabdomyolysis [8]
- External cooling: Mists, fans, surface thermoregulation devices; acetaminophen 1000 mg q6h [8]
- DVT prophylaxis: Subcutaneous heparin or enoxaparin [8]
- Stress ulcer prophylaxis if mechanically ventilated [8]
Dopaminergic restoration (the cornerstone)
- Reinstate levodopa/carbidopa at prior dose via NG/OG tube if unable to swallow [1][7]
- IV amantadine 200 mg BID–TID if available
- Subcutaneous apomorphine — rapid onset; useful when enteral route unavailable [12]
- Subcutaneous foslevodopa — emerging option, case reports support efficacy [11]
Adjunctive therapies
- Bromocriptine 2.5 mg PO/NG q8h (dopamine agonist) [7-8]
- Dantrolene 1–2.5 mg/kg IV for severe rigidity/hyperthermia (monitor LFTs) [1][8]
- Lorazepam for mild rigidity [8]
- High-dose IV methylprednisolone — limited evidence from one small RCT [2]
- ECT — reserved for refractory, life-threatening cases [8]
Manage complications
- Correct electrolytes (K⁺, Ca²⁺, Mg²⁺) [8]
- Dialysis for severe hyperkalemia, volume overload, or refractory AKI [8]
- Treat identified infections with appropriate antibiotics [1]
- Manage BP instability with clonidine or calcium-channel blockers (clevidipine, nicardipine) [8]
- Dexmedetomidine for agitation/delirium (avoids antipsychotics) [8]
17. Disposition
Admission criteria (essentially all true akinetic crises)
- ICU admission for hyperthermia, hemodynamic instability, respiratory compromise, rhabdomyolysis, or altered consciousness [8-9]
- Step-down/telemetry for milder presentations with stable vitals but inability to take oral medications
Observation indications
- Subacute motor worsening without fever or CK elevation — may represent the milder end of the akinetic spectrum [3]
- Prolonged "off" episodes requiring medication adjustment and monitoring
Specialist consultation triggers
- Neurology/Movement Disorders: All cases — urgent consultation for medication management [18]
- Critical Care/ICU: Severe cases with organ dysfunction
- Nephrology: If AKI or need for dialysis
- DBS team: If device malfunction suspected [2][6]
Discharge criteria
- Resolution of hyperthermia and autonomic instability
- Able to tolerate oral dopaminergic medications
- CK trending down, renal function stable
- Return to near-baseline motor function
18. Follow Up / Return Precautions
Follow-up timing
- Neurology/Movement Disorders follow-up within 1 week of discharge
- PCP within 1–2 weeks for medication reconciliation
Return precautions — instruct patient/caregiver
- Never abruptly stop levodopa or other PD medications — this is the single most important counseling point [1][5]
- Return immediately for fever >38°C, worsening rigidity, confusion, inability to swallow, dark urine, or falls
- Bring a complete, time-specific medication list to every ED visit and hospitalization
- Patients should carry a "Parkinson's Alert Card" noting time-critical medications [15]
Expected recovery
- With prompt treatment, ~69% recover to pre-crisis baseline [5]
- Recovery typically occurs over days to weeks
- Permanent worsening of PD and fatalities have been reported despite treatment [2]
- Critical illness neuromyopathy may complicate recovery — suspect if rigidity resolves but persistent weakness remains [9]
References
1. Prevention and Treatment of Malignant Syndrome in Parkinson's Disease: A Consensus Statement of the Malignant Syndrome Research Group. — Ikebe S, Harada T, Hashimoto T, et al. Parkinsonism & Related Disorders. 2003.
2. Movement Disorders Emergencies Part 1: Hypokinetic Disorders. — Robottom BJ, Weiner WJ, Factor SA. Archives of Neurology. 2011.
3. The Akinetic Crisis in Parkinson´s Disease- The Upper End of a Spectrum of Subacute Akinetic States. — Pötter-Nerger M, Schrader C, Jost WH, Höglinger G. Journal of Neural Transmission. 2024.
4. Emergencies in Parkinsonism: Akinetic Crisis, Life-Threatening Dyskinesias, and Polyneuropathy During L-Dopa Gel Treatment. — Onofrj M, Bonanni L, Cossu G, et al. Parkinsonism & Related Disorders. 2009.
5. A Collaborative Study on the Malignant Syndrome in Parkinson's Disease and Related Disorders. — Takubo H, Harada T, Hashimoto T, et al. Parkinsonism & Related Disorders. 2003.
6. Recent Developments in Drug-Induced Movement Disorders: A Mixed Picture. — Factor SA, Burkhard PR, Caroff S, et al. The Lancet. Neurology. 2019.
7. Malignant Syndrome in Parkinson's Disease: Concept and Review of the Literature. — Mizuno Y, Takubo H, Mizuta E, Kuno S. Parkinsonism & Related Disorders. 2003.
8. Neuroleptic Malignant Syndrome. — Wijdicks EFM, Ropper AH. The New England Journal of Medicine. 2024.
9. Critical Illness Neuromyopathy Complicating Akinetic Crisis in Parkinsonism: Report of 3 Cases. — Capasso M, De Angelis MV, Di Muzio A, et al. Medicine. 2015.
10. Emergency Presentations of Parkinson's Disease: Early Recognition and Treatment Are Crucial for Optimum Outcome. — Ghosh R, Liddle BJ. Postgraduate Medical Journal. 2011.
11. Subcutaneous Foslevodopa in Akinetic Crisis. A Case Report From the Neurological Intensive Care Unit. — Loeffler MA, Mengel A, Single C, Weiss D, Feil K. Frontiers in Medicine. 2024.
12. Parkinson’s Disease. — Tanner CM, Ostrem JL. The New England Journal of Medicine. 2024.
13. Alternative Treatments to Selected Medications in the 2023 American Geriatrics Society Beers Criteria®. — Steinman MA. Journal of the American Geriatrics Society. 2025.
14. Medical, Surgical, and Physical Treatments for Parkinson's Disease. — Foltynie T, Bruno V, Fox S, et al. Lancet. 2024.
15. An Underrecognized Problem: Missed and Delayed Carbidopa-Levodopa Administration in Emergency Department Patients With Parkinson's Disease. — Elder NM, Lash EM, Tomkins-Tinch C. Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine. 2026.
16. Diagnostic and Statistical Manual of Mental Disorders. — Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et al American Psychiatric Association (2022). 2022.
17. Dopamine Transporter Single-Photon Emission Computerized Tomography Supports Diagnosis of Akinetic Crisis of Parkinsonism and of Neuroleptic Malignant Syndrome. — Martino G, Capasso M, Nasuti M, et al. Medicine. 2015.
18. When Time Is of the Essence: Managing Care in Emergency Situations in Parkinson's Disease. — Prasad S, Pal PK. Parkinsonism & Related Disorders. 2019.